Norethindrone in Serum After use of an oral Contraceptive Containing Norethindrone Acetate

1983 ◽  
Vol 62 (1) ◽  
pp. 71-76 ◽  
Author(s):  
N. N. Sarkar ◽  
V. Laumas ◽  
N. Agarwal ◽  
V. Hingorani ◽  
K. R. Laumas
2001 ◽  
Vol 1 (3) ◽  
pp. 123-131 ◽  
Author(s):  
J. Michael Maloney ◽  
Deborah I. Arbit ◽  
Mary Flack ◽  
Constance McLaughlin-Miley ◽  
Cynthia Sevilla ◽  
...  

1970 ◽  
Vol 53 (4) ◽  
pp. 831-833
Author(s):  
John Y P Wu

Abstract Norethindrone, norethindrone acetate, dimethisterone, medroxyprogesterone acetate, and norethynodrel are determined in oral contraceptive tablets. For the first 4 compounds, a chloroform extract of the tablets is treated directly with isonicotinyl hydrazide reagent to produce a stable color which is measured at 380 nm. The chloroform extract of norethynodrel tablets is isomerized before the reagent is added. An intralaboratory study gave good results, with standard deviations of 0.74 to 1.21%. A collaborative study is recommended.


2016 ◽  
Vol 2016 ◽  
pp. 1-3
Author(s):  
Michelle S. Min ◽  
Rob Fischer ◽  
John B. Fournier

Erythema nodosum is a septal panniculitis that typically presents as symmetric, tender nodules on the anterior aspects of bilateral lower extremities. Nearly half of cases are due to secondary causes, with oral contraceptive pills being the leading pharmaceutical cause. However, to our knowledge, there has yet to be a published association with norethindrone acetate, ethinyl estradiol, and ferrous fumarate. We report our experience with a 30-year-old woman who developed unilateral tender nodules within a month of starting 1 mg norethindrone acetate and 20 mcg ethinyl estradiol daily. Of note, she had previously taken oral contraceptives with the same estrogen agent but different progesterone, without problems. We conclude that systemically triggered erythema nodosum can present with lesions localized to one extremity. When a patient presents with tender, firm nodules, clinicians should consider the possibility of erythema nodosum and its triggers, such as oral contraceptives. Additionally, should a patient on hormonal therapy develop erythema nodosum, changing the progesterone agent may allow the patient to continue similar therapy without developing symptoms.


2013 ◽  
Vol 122 (3) ◽  
pp. 601-607 ◽  
Author(s):  
David F. Archer ◽  
Steven T. Nakajima ◽  
Allan T. Sawyer ◽  
Jeffrey Wentworth ◽  
Suzanne Trupin ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document